

P&T Members Present: Tara Higgins, RPh, CGP, CDOE

Rita Marcoux, RPh, MBA, Co-chairperson

Kristina Ward, Pharm D

David Feeney, RPh, Chairperson

Cynthia Barry, MSW

Gregory Allen, MD

L. McIntyiere Johnston, MD

Richard Wagner, MD

Mathew Salisbury, MD

Others Present: Paula Avarista, RPh, MBA (RI Medical Assistance Program)

Ray Maxim, MD (RI Medical Assistance)

Barbara Metz, RN (Electronic Data Systems)

Dawn Rousseau (Electronic Data Systems)

Karen Mariano, RPh (Electronic Data Systems)

Chris Andrews, Pharm D (Coventry Health Systems)

Chaz Gross (NAMI-RI)

The meeting was called to order by Chairperson Feeney at 8:10 AM. After welcoming and introductory remarks, the public comments portion began. Representatives from the following Pharmaceuticals Manufacturing Companies gave presentations: Sanofi-Aventis, Daiichi-Sankyo and GlaxoSmithKline. Also commentary was given by

Verna Suneeth, MD.

Chris Andrews from Coventry Health Systems gave an overview of the drug classes that were on the agenda to be reviewed.

The Chairperson recessed the committee to executive session to discuss proprietary information. Voting took place at this time. (See attached sheet for voting results).

The committee returned to open session and the chairperson presented the committee's recommendation for drugs to be included on the PDL.

The chairperson adjourned the meeting at 11:15 AM.